While some biotechnology and pharmaceutical companies are working to develop potentially effective therapies and vaccines for COVID-19, many who are focused on other therapeutic areas are working to identify the best strategies to keep their clinical development programmes on track or to rapidly restructure them.
As plans are being developed, there are many uncertainties about what the future holds, as well as the longerterm implications on clinical research in terms of timing, patient identification and access, design and protocols. A team of CRA Life Sciences experts conducted a recent analysis involving interviews with a range of industry stakeholders including regulatory and policy experts, venture capitalists and contract research organisations (CROs) to try to better understand both the short- and long-term impacts of COVID-19 on clinical development programmes.
To read the analysis published in PMLiVE, click here.
